Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 palivizumab-controlled trial of clesrovimab (MK-1654) for RSV prophylaxis in high-risk infants
2022-500752-39-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, single-blind trial of clesrovimab-cfor in respiratory syncytial virus disease (RSV) and respiratory syncytial virus lower respiratory tract infection (3 arms), sponsored by Merck & Co. Primary endpoints: Solicited injection-site adverse events in RSV Season 1, Solicited fever based on daily body temperature in RSV Season 1 and 5 more. Started May 2023; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on 2022-500752-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500752-39-00.